Affordable Access

Publisher Website

SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT GLYCOSYLATED INTERLEUKIN 6 IN PATIENTS WITH CANCER: PHARMACOKINETICS, PHARMACODYNAMICS AND IMMUNOMODULATORY EFFECTS

Authors
Publisher
Elsevier Ltd
Publication Date
Volume
12
Issue
4
Identifiers
DOI: 10.1006/cyto.1999.0556
Keywords
  • Interleukin 6/Glycosylated/Pharmacokinetics/Clinical Trial/Immunomodulation
Disciplines
  • Biology
  • Pharmacology

Abstract

Abstract This is the first report of the serum profile of a glycosylated recombinant form of human IL-6 (rhIL-6) administered subcutaneously (1–10 μg/kg/day) in a phase I/II trial as a thrombopoietic agent in patients with advanced cancer. The pharmacodynamic effects of IL-6 were also examined. Detailed pharmacokinetic measurements were made in four patients. Peak concentrations at 5–8 h and a median t 0.5of ca. 5 h were similar to those previously reported for non-glycosylated IL-6. However, higher peak concentrations and apparent differences in effective dose levels to those previously reported with the non-glycosylated form were seen. Indications of an apparent attenuation in circulating IL-6 concentrations with continuing injections were seen in eight of 10 patients examined but anti-IL-6 antibody generation was seen in only two patients. Soluble interleukin 6 receptor concentrations generally decreased. No major changes in T cell subsets were seen but expression of CD25 and CD54 by T lymphocytes significantly increased, accompanied by marked increases in soluble CD25 (sIL-2R) and CD54 (sICAM-1). No consistent change in B cells, monocytes or NK cells were seen. No evidence for induction of TNF-α was found. This study demonstrates similar biological effects of glycosylated rhIL-6 to those reported for the non-glycosylated form but illustrates several apparent differences which are discussed further.

There are no comments yet on this publication. Be the first to share your thoughts.